Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning

[cafead]

via Despite winning FDA approval on Friday for its sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel), bluebird bio’s investors were less than bullish on the company. The Massachusetts-based biotech closed the day down nearly 35%.

article source